43 results about "U937 cell" patented technology

The invention provides a method for preparing Bailing tablets. The Bailing tablets are prepared from 194g of Chinese angelica, 42g of pseudo-ginseng, 83g of safflower, 167g of peony bark, 83g of peach kernel, 167g of divaricate saposhnikovia root, 167g of atractylodes, 42g of angelica root, 417g of purslane, 83g of red peony root and 194g of astragalus root serving as raw medicaments by adopting supercritical extraction and microwave extraction, so that the ferulic acid content is greatly improved. The invention also provides application of the Bailing tablets in preparation of a medicament for inhibiting propagation of human histiocytic lymphoma U937 cells.

The invention discloses a polyoxometalate compound modified by amino acid.The compound has the general formula of Am[B3XMo6O21].nH2O and is prepared through the steps of dissolving Na2MoO4.H2O, Se, As, Sb or Bi oxide, glycine, alanine, histidine, lysine, tryptophan, phenylalanine, methionine, threonine, isoleucine, leucine or arginine and KCl in H2O, putting the solution on a magnetic stirrer to be mixed and stirred, adjusting pH of the solution to be 3.4 to 3.6 through HCl, stirring and heating reflux for 0.5-2 hours, conducting cooling and filtering, standing for 1-2 days, and collecting crystals.It is determined through the MTT method that the IC50 value of HL-60 cells is 0.127 microM, the IC50 value of U937 cells is 2.731 microM, the IC50 value of U937 cells is 2.731 microM, and the IC50 value of HUVECs cells is 889.18 microM.The polyoxometalate compound is high in leukemia resistant activity, low in toxicity and low in price.

The invention belongs to the field of traditional Chinese medicine preparations, and particularly provides a preparation method of osteoproliferation removal tablets. The osteoproliferation removal tablets comprise the active pharmaceutical ingredients of 208 g of prepared rehmannia roots, 140 g of caulis spatholobi, 140 g of herba epimedii, 140 g of rhizoma drynariae, 140 g of rhizoma cibotii, 70 g of semen raphani, 70 g of wolfberry fruits, 140 g of cynomorium songaricum and 70 g of himalayan teasel roots. The osteoproliferation removal tablets are prepared from cationic resin in a supercritical extraction mode, the content is greatly increased, and the dosage is decreased. The invention further provides the application of the osteoproliferation removal tablets in preparing medicine for restraining proliferation of human tissue cell lymphoma U937 cells.

The invention provides a histone deacetylases (HDACs) inhibitor compound N<1>-(6-(hydroxyamino)-6-oxohexyl)-N<4>-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthyl)terephthalamide having an obvious inhibitory effect on both HDACs and human leukemia U937 cell growth and proliferation, wherein the inhibitory effect is significantly stronger than that of a common HDACs inhibitor trichostatin TSA. The invention also provides a preparation method and a process route of the compound.

The invention provides a preparation method of a bupleurum tenue capsule. The bupleurum tenue capsule is prepared from the following active pharmaceutical ingredients: 445g of bupleurum tenue, 222g of pinellia ternata stir-baked with ginger juice, 167g of scutellaria baicalensis, 167g of codonopsis pilosula, 167g of liquorice, 167g of fresh ginger and 167g of Chinese dates. The bupleurum tenue capsule is prepared by means of supercritical extraction, so that the content of active ingredients is increased greatly and the dosage is reduced. The invention also provides the applications of the bupleurum tenue capsule in preparing medicines for inhibiting proliferation of human histocyte lymphoma U937 cells and medicines for increasing red blood cells.

The present invention relates to an application of CoCl2 in preparation of medicine in treating leucosis. The common low oxygen environment analog compound can effectively inhibit degradation of HIF-1 alpha in the leucosis cell so as to induce differentiation of leucosis cell. The CoCl2 can combined with arsenic troxide (ATO) and/or all-trans-tretinoin (ATRA) to make matched application. The dose range of CoCl2 is nontoxic dose, its optimum range is 12.5-5.0 micro M. The described leucosis cell can be NB4 cell, U937 cell and Kasumi cell.

The invention relates to a method for producing CCR5 autovaccine, wherein based on the structure of CCR5, it uses linker whose amino acid sequence is GGGGS to connect external four sections of CCR5 cell, to simulate the external structure as rCCR5; inserts T cell assist epitope PADRE into N end of rCCR5; artificially synthesizes PADRE- rCCR5 gene; the target gene is colon into represent carrier of pBV-220 corn; transfers bacillus coli, to represent effect in it; washes with inclusion body; chromatography in gel post; obtaining purified protein; the target protein PADRE-rCCR5 is used as CCR5 polypeptide vaccine antigen, while immunity animal represents that the PADRE-rCCR5 can induce body to generate the antibody with high CCR5 specificity; and the invention uses flow cell check immunity antiserum to test U937 cell of CCR5, which proves that the average combine rate can reach 75. 8%. The invention supports CCR5 autovaccine construction and AIDS vaccine research.

The invention discloses application of a flavonoid derivative GL-V9 and anthracycline antibiotics in preparation of a leukemia treatment medicine, and belongs to the technical field of medicines. It is found that the flavonoid derivative GL-V9 combined with low-dose anthracycline antibiotics can significantly inhibit growth of acute myelogenous leukemia (AML) cells, MTT experiments and U937 cell nude mouse transplantation tumor models verify that the GL-V9 and the low-dose anthracycline antibiotics can play a synergistic anti-AML effect, and the application potential of the combined administration mode in treatment of AML is prompted.

The invention discloses an application of panatinib in the preparation of a medicament for treating influenza virus infection. The applicant tests the toxicity of panatinib to cells on human monocyteseries U937 and tests the secretion inhibitory effect of panatinib on the three important inflammatory factors IL-8, IP-10 and MCP-1 in U937 cell line in a non-toxic or low-toxic concentration range.The result shows that the small-molecular compound has significant anti-inflammatory activity and dose-dependent effect. In a lethal mouse influenza infection model, panatinib is used for treating infected mice, and can effectively reduce the concentration of inflammatory factors in lung lavage fluid of the infected mice, delay the reduction speed of the weight of the mice, and improve the survival rate of the mice. Therefore, the panatinib disclosed by the invention is a novel anti-inflammatory drug aiming at influenza, has the advantages of good safety, high selection index and effective animal model experiments, can be used for developing drugs for treating influenza virus infection, and has wide application prospect.

The invention discloses application of a human-derived monocytic series U937 in preparation of an anti-influenza virus and a drug screening model of an inflammation factor induced by the virus. In the application, an influenza virus can effectively infect a U937 cell line and can induce a series of important inflammatory factor expressions including MCP-1, IP-10, IL-8, IL-6 and the like, and the toxicity and antiviral and anti-inflammatory activity of drugs can be comprehensively evaluated in a round of experiments by detecting the activity of injected cells, the virus level in supernatant and the level of relevant inflammatory factors. The established cell screening model is accurate, efficient, low in cost, short in consumed time and free of deviation property and can be used for high throughput screening of antiviral and anti-inflammatory drugs for treating the influenza virus.

The invention provides an ursolic acid derivative and a preparation method thereof. The ursolic acid derivative is bearberry alkane-12-alkene-28-acyl (8'-aminocaprylicacid). The preparation method of the ursolic acid derivative comprises the following steps: firstly, ursolic acid is converted into a crude product of a 3-O-acetyl bearberry alkane-28-acyl chloride intermediate through two steps, then the crude product is used as one of reactants to react with 8-aminocaprylicacid, and finally the crude product and a sodium hydroxide solution are subjected to hydrolysis reaction, so that the ursolic acid derivative is obtained. Compared with the ursolic acid derivative in the prior art, the ursolic acid derivative provided by the invention has more obvious and better effects on the aspect of inhibiting human body leukemia U937 cell proliferation; the preparation method has few steps, the purification method is simple, the cost can be reduced, and the product purity is high.

The invention discloses a novel protein AGGF1 with high anti-inflammatory performance, FHA polypeptide of the protein AGGF1 and application of the FHA polypeptide in preparation of an anti-inflammatory drug, and belongs to the field of biological medicine. The FHA polypeptide represented by SEQ ID NO:1 in a sequence list and the protein AGGF1 represented by SEQ ID NO:2 in the sequence list are expressed through cloning; and effects of the FHA polypeptide and the protein AGGF1 in an endothelial cell HUVEC and mononuclear cell U937 adhesion process, effects of the FHA polypeptide and the protein AGGF1 for expressing inflammatory factors E-Selectin, ICAM and IL-8 in the endothelial cells HUVEC and effects of the FHA polypeptide and the protein AGGF1 for inhibiting the activity of an NF-kB starter are checked, so that the FHA polypeptide and the protein AGGF1 can be found to be capable of inhibiting the activation of the blood vessel endothelium and then further inhibiting the generation of vascular inflammation. Therefore, the polypeptide comprised in an amino acid sequence provided by the invention or consisting of the SEQ ID NO:1 or the SEQ ID NO:2 can be effectively used for preparing the anti-inflammatory drug and lays the foundation for the preparation of broad-spectrum anti-inflammatory drugs and the prevention or treatment of inflammation related diseases.

The invention provides application of triptonide in preparation of a medicine for treating acute monocyte leukemia, and belongs to the technical field of leukemia medicines. According to the application of the triptonide in preparation of the medicine for treating the acute monocyte leukemia, acute monocyte leukemia cells U937 are taken as research objects, U937 cells are treated by a triptonide solution, the cell activity of the U937 cells is detected by an MTT method, and the result shows that the triptonide has an effect of inhibiting proliferation of the U937 leukemia cells. The influenceof the triptonide on apoptosis of the U937 cells is detected by an Annexin V/PI double staining method, and the result shows that the triptonide can induce apoptosis of the U937 cells, and the apoptosis is more obvious along with increase of concentration. Therefore, the triptonide can inhibit proliferation of the acute leukemia cells and induce apoptosis, so that treatment of the acute monocyte leukemia is realized.

The invention discloses an ursolic acid derivative and a preparation method thereof. The ursolic acid derivative is ursolic acid-12-alkene-28-acyl(7'-aminoheptylic acid) or ursolic acid-12-alkene-28-acyl(paraaminomethylbenzoicacid). The preparation method comprises the following steps of: transforming ursolic acid into a crude product of a 3-O-acetyl ursolic acid-28-acyl chloride intermediate in two steps; reacting with 7-amino ethyl heptylate hydrochloride or paraaminomethylbenzoicacid methyl ester hydrochloride by taking the crude product as one of reactants; and hydrolyzing with a sodium hydrate aqueous solution to obtain the ursolic acid derivative. The ursolic acid derivative has a good effect on inhibiting the human leukemias U937 cell proliferation which is not achieved in the prior art; and the preparation method has the advantages of small quantity of synthesis reaction steps, simple purification method, saving in cost and high product purity.

The invention discloses application of dasatinib in preparing drugs for treating influenza virus infection. The toxicity of the dasatinib on cells is detected on a human monocytic line U937, then within the concentration range of nontoicity or low toxicity, the secretion inhibition effect of the dasatinib on three important inflammatory factors of IL-8, IP-10 and MCP-1 in the cell line U937, and results show that the small-molecular compound has significant anti-inflammatory activity and shows a doseage-dependent effect. In a fatal mouse influenza infection model, the dasatinib is utilized fortreating an infected mouse, the concentration of the inflammatory factors in lung washing liquid of the mouse can be effectively lowered, the weight lowering speed of the mouse is lowered, and the survival rate of the mouse is increased. Therefore, the dasatinib is a novel anti-inflammatory drug for influenza, has the advantages that the safety and selection index are high, and animal model experiments are effective, can be used for developing drugs for treating the influenza virus infection, and has a wide application prospect.

The invention provides a preparation method of a perillaseed qi depressing pellet. The pellet is prepared from 160 g of fried perillaseed, 160 g of mangnolia officinalis, 160 g of common hogfenneI root, 160 g of liquorice, 160 g of ginger processed pinellia, 160 g of dried orange peel, 112 g of agilawood and 112 g of angelica sinensis as raw material medicines through supercritical fluid extraction. Therefore, the content is greatly increased, and the dosage is reduced. The invention further provides application of the perillaseed qi depressing pellet in preparing a medicament for inhibiting cell proliferation of human histocyte lymphoma U937.

The invention provides novel application of Java brucea fruit oil emulsion injection to the anticancer aspect, in particular to novel application to the anti-leukemia aspect. The invention respectively uses humanized leukemia U937, NB4 and HL-60 cell strains and humanized prostatic carcinoma Du145 cell strains as target cells, and studies the inhabiting effect of the Java brucea fruit oil emulsion injection on the blood system tumor and the urogenital system tumor. The invention discovers that the Java brucea fruit oil emulsion injection has the inhabiting effect on the humanized leukemia HL-60, NB4 and U937cell strains and the humanized prostatic carcinoma Du145 cell strains for the first time, and the inhabiting effect is improved along with the gradual increase of the dosage. In addition, the Java brucea fruit oil emulsion injection can also induce the apoptosis of the humanized leukemia cells, and also has the apoptosis induction effect on the primary dissociated leukemia cells. In addition, the bruceolic oil emulsion injection liquid has low cell toxic effect on peripheral blood lymphocytes of normal persons. The results show that the Java brucea fruit oil emulsion injection has certain potential in the aspect of leukemia treatment, and can provide high-efficiency and low-toxicity medicine for the leukemia treatment.

The invention relates to a targeted poly (D, L-lactic acid-co-glycolic acid) (PLGA) nano-drug complex of glycyrrhetinic acid for treating solid tumors and hematoma and a preparation method thereof, and the preparation method mainly comprises the following steps: 1) extracting U937 cell membrane vesicles; (2) synthesizing a glycyrrhetinic acid-PLGA drug-loaded nano core; and (3) fusing the cell membrane vesicles and the drug-loaded GA/PLGA nano particles, so as to obtain the glycyrrhetinic acid (GA)-loaded cell membrane coated poly (D, L-lactic acid-co-glycolic acid) nano drug (GCMNPs). The nano-drug has a typical core-shell structure and good monodispersity and stability. GGA entrapment efficiency is high, the process of releasing GA from GCMNPs is time-dependent, and GA can be quickly released in a tumor environment, so that side effects during chemotherapy can be relieved. The GCMNPs nano-drug has a tumor targeting capability, and can selectively inhibit the growth of solid tumor and hematoma cells at a relatively low drug concentration.